Utilization of Rescue and Facilitated Angioplasty for Primary PCI: Who Should Get Lytic Therapy in 2009? Adnan Kastrati Deutsches Herzzentrum, Technische.

Slides:



Advertisements
Similar presentations
Patient Oriented Therapy for STE-MI
Advertisements

STOPAMI 1 & 2 Predictive Factors and Impact of No-Reflow After Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction.
Facilitated PCI & rescue PCI Dolly mathew. Primary PCI is the preferred reperfusion strategy in STEMI Most patients donot arrive at the PCI center within.
Presented by: Fahim H. Jafary, M.D., F.A.C.C. Associate Professor of Medicine Aga Khan University Hospital, Karachi March 14, 2008 Primary Percutaneous.
The FINESSE Trial: Results of the Formal Low Molecular Weight Heparin Substudy Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events.
Optimal Timing of PCI in ACS Patrick Hildbrand. Trends and Prognosis in ACS Furman MI, JACC 2001, 37: Hospital 1 year.
The Pivotal Role of Platelets in Primary PCI Paul Martin PhD Senior Medical Affairs Scientist Centocor/ Eli Lilly UK/Eire/Nordic regions.
Relationship of Time to Treatment and Door-to-Balloon Time to Mortality in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty Christopher.
Management of Acute Myocardial Infarction Minimal Acceptable vs Optimal Care Hussien H. Rizk, MD Cairo University.
J. Mehilli, MD, G. Richard, F-J. Neumann, S. Massberg, K-L. Laugwitz, J. Pache, J. Hausleiter, I. Ott, M. Fusaro, T. Ibrahim, A. Schömig, A. Kastrati Deutsches.
ISAR-TEST 5: Randomized, Non-inferiority Trial of Rapamycin/Probucol- and Zotarolimus-Eluting Stents J. Mehilli, MD A. Kastrati, R.A. Byrne, S. Massberg,
Improved Care for Acute Myocardial Infarction Linking Referral and Receiving Centres – How can We Communicate Better? Dr. James McMeekin AMI Faculty Cardiologist,
Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.
Primary PCI Treatment of choice for Acute MI.
Time Is Myocardium and the Wavefront of Necrosis CM Gibson 2002.
Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.
GUSTO I GUSTO I Median Time (hrs) Between Symptom Onset and Treatment GUSTO III GUSTO III InTIME II InTIME II ASSENT.
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing.
ACS and Thrombosis in the Emergency Setting
MD DM DNB FACC FICC FCSI FESC LAKSHMI HOSPITAL, PALAKKAD.
Advanced Cardiovascular Intervention 2009 Timings in PPCI: Have we learnt the lessons from our European Colleagues? Peter F Ludman.
A modern thrombolysis service is superior to primary angioplasty
A H Gershlick University Hospital of Leicester UK A H Gershlick University Hospital of Leicester UK AA 2008 Who should we rescue ?
Prehospital Fibrinolysis with Double Antiplatelet Therapy in Acute ST-Elevation Myocardial Infarction: The Clarity Ambulance Substudy Prehospital Fibrinolysis.
1 Primary Angioplasty for Acute STEMI Dr Adam Jacques Dr Sola Odemuyiwa February 2010.
Role of Percutaneous coronary intervention (PCI) after thrombolytic therapy By Dr. Mohamed Mahros Assistant lecturer of cardiology Benha faculty of medicine.
To Transfer or Not to Transfer? The debate between transfer for PCI versus local thrombolysis. Todd Ring, BSc., MD, CCFP March 11, 2004 University of Calgary.
Patient Transfer Mark de Belder The James Cook University Hospital Middlesbrough.
Is PCI necessary for AMI related artery with TIMI 3 flow ? Donghoon Choi Yonsei Cardiovascular Center Yonsei University College of Medicine.
Primary Angioplasty and Hemodynamic Support in Cardiogenic Shock Department of Internal Medicine, College of Medicine, Yonsei University Hyuck Moon Kwon,
ACS differentiation: With or without ST- elevation STEMI NSTEMI UAP.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
ISAR REACT 3 A. Kastrati, F.-J. Neumann, J. Mehilli, S. Schulz, G. Richardt, R. Iijima, R.A. Byrne, P.B. Berger, A. Schömig Bivalirudin Versus Unfractionated.
Myocardial Ischaemia National Audit Project Are we replacing good fibrinolytic treatment with poor primary PCI? John Birkhead who has NO CONFLICT OF INTEREST.
Advanced Angioplasty 2005 Primary PCI making it happen Data collection and Timings Peter Ludman University Hospital Birmingham.
Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial Presented at American Heart Association Scientific Sessions 2004 Presented.
Lysis and Beyond: ESC Guidelines and Reality J N Townend Queen Elizabeth Hospital Birmingham.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Infarct transmurality and infarct size assessed by delayed enhancement magnetic resonance imaging: Association.
West Hertfordshire Primary Angioplasty Service Masood Khan.
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty:
Keith Dawkins MD FRCP FACC Southampton University Hospital UK Is Primary Angioplasty Equally Effective in Both Men and Women ?
Enoxaparin in primary PCI From FINESSE to ATOLL G. Montalescot Institut de Cardiologie Pitié-Salpêtrière Hospital Paris, France The FINESSE Trial is supported.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
A Randomized, Double-blind, Placebo-controlled Trial of Intravenous Erythropoietin in Patients with ST-Segment Elevation Myocardial Infarction – Primary.
S. Chiu Wong MD, FACC Associate Professor of Medicine Weill Medical College of Cornell University Director, Cardiac Catheterization Laboratories The New.
Transfers, Facilitated and Rescue PCI for AMI Michael J Cowley, M.D., FSCAI Nothing to disclose.
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2007 Focused Update of the ACC/AHA 2004 Guidelines.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
Challenges in Pre Hospital Diagnosis & Management of Acute MI
The American College of Cardiology Presented by Dr. Adnan Kastrati
Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:
MCV Campus Ginger Edwards.
Deutsches Herzzentrum, Technische Universität, Munich, Germany
Figure 1 PCI strategies in patients with STEMI and multivessel disease
AMISTAD II: Study Design
Published in the European Heart Journal
Impact of Diabetes Mellitus on Long-term Outcomes in the
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
MRRs and EMRRs for women with ACS
16-year follow-up of the DANish Acute Myocardial Infarction 2 (DANAMI-2) trial PG Thranea, SD Kristensena, KKW Olesena, LS Mortensenb, HE Bøtkera, L.
Presentation transcript:

Utilization of Rescue and Facilitated Angioplasty for Primary PCI: Who Should Get Lytic Therapy in 2009? Adnan Kastrati Deutsches Herzzentrum, Technische Universität Munich, GERMANY CRT 2009 Washington

elig. treated 20% elig. untreated 15% too late 35% age > 75yrs 15% CI 15% equivocal ECG 10% <1990 n= Muller & Topol, Ann Intern Med 1990 Who Should not Get Thrombolysis in 2009  Patients with contraindications to thrombolysis

Fibrinolysis % Salvage Index PCI <=2h2-6h6-12h12-48h Schömig et al, EHJ 2006 BRAVE-2 Substudy, Am Heart J 2006 Conservative Time Dependence of Efficacy of Lytic Therapy

Fibrinolysis % 30d Death PCAT-2, EHJ pts h1-2h2-3h3-6h6-12h Time Dependence of Efficacy of Lytic Therapy

Who Should not Get Thrombolysis in 2009  Patients with contraindications to thrombolysis  Patients presenting after 6 hours from symptom onset

day mortality Adjusted odds ratio PCIThrombolysis favors PCI favors Thrombolysis - 36% P<0.001 All - 31% <2 h n= % 2-6 h n=3492 % PCAT-2, EHJ 2006 Should Thrombolysis Be Preferred in Patients Presenting Very Early?

 Patients with contraindications to thrombolysis  Patients presenting after 6 hours from symptom onset  Thrombolysis should not be preferred over PCI even for patients presenting < 2 hours from symptom onset Who Should not Get Thrombolysis in 2009

Nallamothu, Bates. AJC 2003Betriu, Masotti. AJC 2005 Should Use of Thrombolysis Be Dependent on Assumptions of PCI-Related Delays?

Can our decision clock rely on the accuracy of these studies? PCAT-2, EHJ 2006 National Registry of Myocardial Infarction, Circ 2006 Should Use of Thrombolysis Be Dependent on Assumptions of PCI-Related Delays?

 Patients with contraindications to thrombolysis  Patients presenting after 6 hours from symptom onset  Thrombolysis should not be preferred over PCI even for patients presenting < 2 hours from symptom onset  It is very questionable to use thrombolysis based on inaccurate assumptions on PCI-related delay Who Should not Get Thrombolysis in 2009

Should Thrombolysis Be Used for Facilitated PCI? ASSENT-4, The Lancet 2006 Thrombolysis alone

Should Thrombolysis Be Used for Facilitated PCI? Thrombolysis + GP IIb/IIIa Inhibitors BRAVE, JAMA 2004 P=0.81 reteplase+abciximab abciximab % P=NS % Final infarct sizeAdverse events

Should Thrombolysis Be Used for Facilitated PCI? FINESSE, NEJM 2008

Who Should not Get Thrombolysis in 2009  Patients with contraindications to thrombolysis  Patients presenting after 6 hours from symptom onset  Thrombolysis should not be preferred over PCI even for patients presenting < 2 hours from symptom onset  It is very questionable to use thrombolysis based on inaccurate assumptions on PCI-related delay  Thrombolysis, alone or with IIb/IIIa inhibitors, should not be used for “facilitated PCI”

Should Repeat Thrombolysis Be Used After Failed Thrombolysis? Repeated Thrombolysis Conservative MACCE at 12 Months REACT – JACC – in press % Repeated Thrombolysis Conservative Mortality at 4 yrs % P=0.48P=0.89

Who Should not Get Thrombolysis in 2009  Patients with contraindications to thrombolysis  Patients presenting after 6 hours from symptom onset  Thrombolysis should not be preferred over PCI even for patients presenting < 2 hours from symptom onset  It is very questionable to use thrombolysis based on inaccurate assumptions on PCI-related delay  Thrombolysis, alone or with IIb/IIIa inhibitors, should not be used for “facilitated PCI”  Thrombolysis should not be used as a repeated therapy after failed thrombolysis

Rescue PCI Conservative MACCE at 12 Months REACT – JACC – in press Rescue PCI Conservative Mortality at 4 yrs % Should Rescue PCI Be Used After Failed Thrombolysis? P=0.004 %

Should Rescue PCI Be Used After Failed Thrombolysis? The only better alternative to rescue PCI is primary PCI!

Use of Reperfusion Therapy in STEMI From 1999 to 2006 (GRACE) GRACE, EHJ PCI Lytics Cons Lytics PCI Cons

Who Should Get Lytic Therapy in 2009? All those patients without contraindications to thrombolysis to whom we are unable to offer expedient primary PCI!